EU-Project

Awarded prestigious EU-grant for drug development planning

Arctic Bioscience is one of 5 Norwegian companies who were granted SME Instrument funding in 2019, of 283 projects in the EU. The grant was awarded by the European Innovation Council for developing a business plan for a new drug to treat psoriasis.

The project “PsoraxPlan” is a feasibility study on the development of Psorax35 as the first and only oral treatment for mild-to-moderate psoriasis with positive effects on co-morbidities.

The objective of PsoraxPlan was to deliver a comprehensive feasibility analysis of the development of HRO350 (formerly named Psorax35) as a medicinal product for the global market to treat mild-to-moderate psoriasis. The feasibility analysis included a thorough assessment of technical, regulatory, market access, and financing feasibility including a risk analysis and risk mitigation plan; esp. a specific feasibility analysis on aspects related to regulatory affairs (systematic review of the literature; outlining the clinical development plan; and the scientific advice meetings with regulatory authorities), clinical development (protocol outlines, budgets, and patient recruitment feasibility), strategic innovation funding (grant screening) as well as further screening of potential marketing partners

The objective of PsoraxPlan was to deliver a comprehensive feasibility analysis of the development of HRO350 (formerly named Psorax35) as a medicinal product for the global market to treat mild-to-moderate psoriasis. The feasibility analysis included a thorough assessment of technical, regulatory, market access, and financing feasibility including a risk analysis and risk mitigation plan; esp. a specific feasibility analysis on aspects related to regulatory affairs (systematic review of the literature; outlining the clinical development plan; and the scientific advice meetings with regulatory authorities), clinical development (protocol outlines, budgets, and patient recruitment feasibility), strategic innovation funding (grant screening) as well as further screening of potential marketing partners.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 877522.

download